BioSpace News Archive

Veloxis Pharmaceuticals A/S announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) seeking a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.

This World Kidney Day, March 8th, The Kidney Foundation of Canada along with the Can-SOLVE CKD Network and the Canadian Society of Nephrology are urging Canadians to learn more about their kidney health.

Trial designed to evaluate the safety and feasibility of the Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection.

New state-of-the-art micro-ultrasound system allows Arkansas Urology’s patients to benefit from the latest imaging technologies

Prevencio Inc. announces its HARTTM AS multi-protein, artificial intelligence (AI)-driven test, which data indicates accurately diagnoses Aortic Stenosis (AS)—a condition with a 50 percent death rate when left untreated.

Controlled Substance Management Program recognized for helping to reduce opioid epidemic.

The warrants were exercised at $0.17, $0.20 or $0.30.

ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced an exclusive federal government business channel sales agreement with Academy Medical, LLC to sell its ReShape Balloon™ and ReShape vBloc™ products to U.S. Department of Defense (DoD) medical facilities.

The oversubscribed round brings Atomwise’s total capital raised to more than $51 million.

Phase 2a Results Published in Annals of Clinical and Translational Neurology Demonstrate Statistically Significant Improvement in Episodic Memory Function in Patients with Alzheimer’s Disease; Company Initiates Phase 2b (REVERSE-SD) Confirmatory Study with Neflamapimod